Amphastar Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Amphastar Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $170.18 million for the year ending 2025.

  • Amphastar Pharmaceuticals, Inc. showed an increase of +12.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
  • XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q2 2013: $55.95 million | Q3 2013: $51.94 million | Q1 2014: $52.14 million | Q2 2014: $64.08 million | Q3 2014: $72.88 million | Q1 2015: $68.59 million | Q2 2015: $74.46 million | Q3 2015: $70.68 million | Q1 2016: $63.33 million | Q2 2016: $66.66 million | Q3 2016: $66.60 million | Q1 2017: $76.77 million | Q2 2017: $82.54 million | Q3 2017: $66.92 million | Q1 2018: $54.55 million | Q2 2018: $48.07 million | Q3 2018: $68.73 million | Q1 2019: $79.10 million | Q2 2019: $120.37 million | Q3 2019: $85.61 million | Q1 2020: $54.85 million | Q2 2020: $87.39 million | Q3 2020: $87.91 million | Q1 2021: $101.60 million | Q2 2021: $105.43 million | Q3 2021: $106.61 million | Q1 2022: $172.63 million | Q2 2022: $166.16 million | Q3 2022: $157.24 million | Q1 2023: $176.62 million | Q2 2023: $148.60 million | Q3 2023: $266.78 million | Q1 2024: $201.15 million | Q2 2024: $189.62 million | Q3 2024: $192.12 million | Q1 2025: $182.78 million | Q2 2025: $187.69 million | Q3 2025: $216.27 million.
  • Over the full 15 years of available data (2011 to 2025), Amphastar Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 216.7%.
  • Historical annual values: Fiscal year 2025: $170.18 million | Fiscal year 2024: $151.61 million | Fiscal year 2023: $144.30 million | Fiscal year 2022: $156.10 million | Fiscal year 2021: $126.35 million | Fiscal year 2020: $92.64 million | Fiscal year 2019: $73.69 million | Fiscal year 2018: $86.34 million | Fiscal year 2017: $65.59 million | Fiscal year 2016: $72.35 million | Fiscal year 2015: $66.07 million | Fiscal year 2014: $67.83 million | Fiscal year 2013: $53.59 million | Fiscal year 2012: $50.21 million | Fiscal year 2011: $53.74 million.
  • Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: